Zepbound
Zepbound is Eli Lilly's tirzepatide-based weight-loss injection. See average pricing, dosing, and which telehealth brands can prescribe it through insurance.
- Manufacturer
- Eli Lilly
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Dose range
- 2.5 mg → 15 mg weekly
- Average monthly cost
- $1,059 without insurance · $25 with most commercial plans
- Insurance covered
- Often, with prior authorization
Overview
Zepbound (tirzepatide) is the weight-loss-labeled version of Mounjaro and the most potent GLP-1-class medication currently available. In the SURMOUNT-1 trial, patients on the 15 mg dose lost an average of 22.5% of body weight over 72 weeks — meaningfully more than semaglutide.
How it works
Tirzepatide is a dual agonist hitting both GIP and GLP-1 receptors. The combined effect on appetite, satiety, and insulin sensitivity drives larger weight loss than single-receptor GLP-1s.
Side effects
- Nausea (most common at dose escalation)
- Diarrhea or constipation
- Decreased appetite, fatigue
- Injection-site reactions
- Rare: pancreatitis, gallbladder disease
Who should consider Zepbound
Adults with obesity or overweight with comorbidities, particularly those who haven't responded adequately to a single-agonist GLP-1 like Wegovy.
Telehealth programs that prescribe Zepbound
Editorial only — not medical advice. Drug pricing and availability change frequently; verify with the prescribing program before relying on any figure on this page.